AKT1 and cancer: In agreement with outcomes of previous research, it was confirmed that by synergisticly arresting cancer cells at G0-G1 and G2-M phases, the combined treatment regimen of Vem and VERU-111 could overcome the Vem-resistance through enhanced apoptosis and compromised Skp2-AKT signaling pathway.